Steven Zeldenrust
Overview
Explore the profile of Steven Zeldenrust including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muchtar E, Gertz M, Kourelis T, Sidana S, Go R, Lacy M, et al.
Leukemia
. 2020 Jul;
34(10):2819.
PMID: 32728185
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
2.
Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar S, et al.
Blood Cancer J
. 2020 Feb;
10(2):20.
PMID: 32098948
In patients with immunoglobulin light-chain (AL) amyloidosis, depth of hematologic response correlates with both organ response and overall survival. Our group has demonstrated that screening with a matrix-assisted laser desorption/ionization-time-of-flight...
3.
Warsame R, Laplant B, Kumar S, Laumann K, Perez Burbano G, Buadi F, et al.
Blood Cancer J
. 2020 Jan;
10(1):4.
PMID: 31913261
Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included...
4.
Muchtar E, Gertz M, Kourelis T, Sidana S, Go R, Lacy M, et al.
Leukemia
. 2019 Nov;
34(4):1135-1143.
PMID: 31758090
We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of...
5.
Nandakumar B, Kumar S, Dispenzieri A, Buadi F, Dingli D, Lacy M, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Nov;
20(1):53-56.
PMID: 31685378
Background: Non-secretory multiple myeloma (NSMM) is a rare subtype of multiple myeloma (MM) characterized by the absence of monoclonal protein in the serum and/or urine. We look at the clinical...
6.
Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi F, Lacy M, et al.
Amyloid
. 2019 Sep;
27(1):13-16.
PMID: 31544536
Response assessment in light chain (AL) amyloidosis is challenging given the low level of circulating free light chains usually seen. Multi-parametric flow cytometry (MFC) from a marrow aspirate was demonstrated...
7.
Muchtar E, Dispenzieri A, Leung N, Lacy M, Buadi F, Dingli D, et al.
Amyloid
. 2019 Jul;
26(sup1):101-102.
PMID: 31343331
No abstract available.
8.
Muchtar E, Gertz M, Lacy M, Go R, Buadi F, Dingli D, et al.
Br J Haematol
. 2019 Jul;
187(5):588-594.
PMID: 31298751
Improvement in survival in Light chain (AL) amyloidosis has been seen over recent decades, enabling more patients to achieve long-term survival. Patients with AL amyloidosis who survived ≥10 years from...
9.
Muchtar E, Gertz M, Kyle R, Lacy M, Dingli D, Leung N, et al.
Mayo Clin Proc
. 2019 Feb;
94(3):472-483.
PMID: 30770096
Objective: To describe the clinical and laboratory characteristics of patients with meticulously typed light chain (AL) amyloidosis. Patients And Methods: Patients (N=592) with biopsy-proven, mass spectrometry-confirmed AL amyloidosis diagnosed from...
10.
Muchtar E, Therneau T, Larson D, Gertz M, Lacy M, Buadi F, et al.
Leukemia
. 2019 Jan;
33(3):811-814.
PMID: 30675009
No abstract available.